IM Cannabis Corp. announced that its common shares commenced trading on the Nasdaq Capital Market on a 30:1 consolidated basis effective August 27, 2026. This reverse stock split reduced the outstanding share count from approximately 18.57 million to roughly 619,000 shares. The company stated this action was taken to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share. Fractional shares were handled via rounding or cancellation, and convertible securities were proportionately adjusted. IM Cannabis Corp. operates in the medical cannabis industry, importing and distributing cannabis products to patients in Israel and Germany.

IM Cannabis Corp. announced a 30-for-1 reverse stock consolidation to support compliance with Nasdaq’s $1.00 minimum bid price requirement. The Board approved the consolidation, expecting an effective date of August 27, 2026, though it may occur on or before September 15, 2026. Post-consolidation, outstanding shares are expected to decrease from approximately 18.1 million to roughly 603,922. Fractional shares will be rounded up if equal to or greater than one-half; otherwise, they will be cancelled. Convertible securities will see proportionate adjustments to exercise and conversion prices. The company has until October 6, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. IM Cannabis Corp. operates in the medical cannabis industry, importing and distributing cannabis products to patients in Israel and Germany.

On August 16, 2026, IM Cannabis Corp. entered into a definitive agreement to sell its European-focused assets via IMC Holdings to Slil.com Holding Ltd., controlled by CEO Oren Shuster. The transaction consideration includes the acknowledgment of C$3 million in prior advance payments and Slil's assumption of liabilities not exceeding C$9.4 million. No new securities will be issued. The deal is expected to improve shareholders' equity by approximately C$3 million, reduce debt, and allow IM Cannabis to focus on its core Israeli medical cannabis operations. Closing is subject to customary conditions, including tax authority approval, with an outside date of September 30, 2026. This filing discloses a significant strategic divestiture and related-party transaction for a company operating in the international medical cannabis industry.

On August 7, 2026, IM Cannabis Corp. closed a private placement raising US$250,000 in gross proceeds through the issuance of convertible notes to an institutional investor. The company received net proceeds of US$225,000 after a 10% original issuance discount. The notes bear interest at 8% per annum, increasing to 14% upon default, and are not repayable in cash; obligations are satisfied solely through conversion into common shares. Conversion occurs at the lower of a fixed price of US$0.122 or 90% of the lowest daily volume-weighted average price over the preceding 20 trading days, subject to a floor of US$0.02436 and a 4.99% beneficial ownership cap. The transaction included warrants to purchase up to 2,052,545 common shares at an exercise price of CAD$0.17 per share, exercisable immediately for five years until August 7, 2031. Proceeds are intended for general corporate purposes. IM Cannabis Corp. operates in the medical cannabis industry, importing and distributing cannabis to patients in Israel and Germany.

Mr. Alon Dayan resigned from the board of directors of IM Cannabis Corp. effective July 26, 2026, citing personal reasons. The resignation was not related to any disagreement with the company's operations, policies, or practices. IM Cannabis Corp. is a medical cannabis company with operations in Israel and Germany.

IM Cannabis Corp. entered into a Note Purchase Agreement on July 1, 2026, to issue a US$225,000 convertible note and warrants to an institutional investor. The note bears an 8.0% annual interest rate and is convertible into common shares at a price determined by the lower of a fixed price of US$0.152 or a variable price based on 20-day VWAP, with a floor price of US$0.0303. The warrants allow the holder to purchase up to 1,483,386 common shares at an exercise price of CAD$0.22 per share. IM Cannabis Corp. operates in the medical cannabis industry, providing products for the Israel and Israel and Germany markets.